Inducible ZnT8 transgenic mouse

Reference number 7935

Sectors: Pharmaceuticals

Industries: Biotechnology

Proposed use

Diabetes research.

Technology overview

The relevant sequence in the transgenic incorporates a bidirectional tetracyclin regulated promoter, which drives expression of both human ZnT8 Myc and firefly luciferase. This allows ZnT8 expression to be controlled by tetracycline and the sites at which it occurs to be easily identified. Zinc transporter 8 (ZnT8), encoded by SLC30A8, is chiefly expressed within pancreatic islet cells, where it mediates zinc (Zn2[1]) uptake into secretory granules. Although a common nonsynonymous polymorphism (R325W), which lowers activity, is associated with increased type 2 diabetes (T2D) risk, rare inactivating mutations in SLC30A8 have been reported to protect against T2D.

Benefits

  • ZnT8 expression controlled by tetracycline and the sites at which it occurs are easily identified.
  • Associated with increased type 2 diabetes (T2D) risk
  • Rare inactivating mutations in SLC30A8 have been reported to protect against T2D.

Intellectual property information

Reagent/material

Inventor

Professor Guy Rutter

Chair in Cell Biology
Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Visit personal site

Contact us about this technology



Contact

Dr Alexandra Skeaping

Industry Partnerships and Commercialisation Officer, Medicine

Dr Alexandra Skeaping is Industry Partnerships and Commercialisation Officer for the Faculty of Medicine at Imperial College London.

Contact Alexandra

+44 (0)20 7594 7021

a.skeaping@imperial.ac.uk

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

Aptamer-based multiplex screening platform

Aptamer-based multiplex screening platform

A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...